Based on the latest clinical practice guidelines of China and the United States, which were named the Chinese Society of Clinical Oncology (CSCO) guideline by CSCO and the National Comprehensive Cancer Network(NCCN) guideline by NCCN, we compared the differences of multidisciplinary team constitutive requirement, the levels of evidence and recommendation, the diagnostic principles, the treatment principles of common head and neck tumors and followup requirements, and explored the causes of the differences and their implications for Chinese oncologists. The NCCN guideline provides us a good example of evidencebased medicine, and plays an impressive role in regulating cancer treatment in China. At the same time, China is still a developing country with unbalanced regional economic and medical development, individualized and precise treatment should be recommended according to the regional economic environment, medical condition and the individual situation of patients while standardization was emphasized.